Your shopping cart is currently empty

Ayanin has vasorelaxant activity, it also may have the potential for use in treating allergic asthma. The IC50 value of Ayanin is 2.2microM for inhibiting interleukin IL-4 production from purified basophils. Ayanin is a non-selective phosphodiesterase1-4 inhibitor and can be used for respiratory disease researches.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $172 | In Stock | In Stock | |
| 5 mg | $363 | In Stock | In Stock | |
| 10 mg | $538 | In Stock | In Stock | |
| 25 mg | $855 | In Stock | In Stock | |
| 50 mg | $1,150 | In Stock | In Stock | |
| 100 mg | $1,550 | In Stock | In Stock | |
| 200 mg | $1,980 | Inquiry | Inquiry |
| Description | Ayanin has vasorelaxant activity, it also may have the potential for use in treating allergic asthma. The IC50 value of Ayanin is 2.2microM for inhibiting interleukin IL-4 production from purified basophils. Ayanin is a non-selective phosphodiesterase1-4 inhibitor and can be used for respiratory disease researches. |
| Targets&IC50 | IL-4:2.2 μM |
| In vitro | Incubation of human leukemia cells with Ayanin diacetate induced G(2)-M phase cell cycle arrest and apoptosis which was prevented by the non-specific caspase inhibitor z-VAD-fmk and reduced by the overexpression of Bcl-x(L). Ayanin diacetate-induced cell death was found to be associated with: (i) loss of inner mitochondrial membrane potential, (ii) the release of cytochrome c, (iii) the activation of multiple caspases, (iv) cleavage of poly(ADP-ribose) polymerase and (v) the up-regulation of death receptors for TRAIL, DR4 and DR5. Moreover, the combined treatment with Ayanin diacetate and TRAIL amplified cell death, compared to single treatments. |
| Molecular Weight | 344.32 |
| Formula | C18H16O7 |
| Cas No. | 572-32-7 |
| Smiles | COc1cc(O)c2c(c1)oc(-c1ccc(OC)c(O)c1)c(OC)c2=O |
| Relative Density. | 1.31g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 245 mg/mL (711.55 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Saline: 3.3 mg/mL (9.58 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.